Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. University of Colorado, Denver, CO, United States

Survival: 16.0 months
Toxicity Grade: 5
Treatments: Chemotherapy
Drugs: Alkeran
Country: United States
City/State/Province: Denver, CO
Hospital: University of Colorado
Journal: Link
Date: 4/2005

Patients: This Phase I study involved 59 patients with advanced malignant cancers: 32 breast cancer, 10 non-Hodgkin lymphoma, 6 germ cell tumors, 4 Hodgkin disease, 4 ovarian cancer, 2 sarcoma, and 1 unknown primary adenocarcinoma. Seventeen patients were men, and forty-two patients were women. All had received at least one chemotherapy treatment prior to the study, and all had at least one metastatic site that included lymph nodes, lung, bone, and liver.

Treatment: The treatment involved three chemotherapeutic agents: docetaxel, melphalan, and carboplatin. The authors increased the docetaxel dosage fourfold in this study.

Toxicity: Five patients died from regimen-related toxicity after developing grade-5 capillary leakage, enterocolitis, or hepatocellular necrosis. Grade 3-4 toxicities also included stomatitis, constipation, diarrhea, myoarthralgias, peripheral neuropathy, skin rash, and hand-foot syndrome.

Results: The median overall survival for all patients was 16 months.

Support: Aventis Pharmaceuticals provided financial support for this study. Aventis manufactures and markets docetaxel.

Correspondence: Yago Nieto, MD

E-mail to a Friend Email Physician More Information